SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-031647
Filing Date
2024-04-09
Accepted
2024-04-09 17:19:20
Documents
15
Period of Report
2024-04-08
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0203573-8k_immucell.htm   iXBRL 8-K 40408
2 AT THE MARKET OFFERING AGREEMENT, DATED APRIL 9, 2024, BY AND BETWEEN IMMUCELL C ea020357301ex1-1_immucell.htm EX-1.1 219301
3 CONSENT AND FIRST AMENDMENT TO ECONOMIC RECOVERY LOAN PROGRAM LOAN AGREEMENT, DA ea020357301ex10-1_immucell.htm EX-10.1 14373
  Complete submission text file 0001213900-24-031647.txt   505074

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE iccc-20240408.xsd EX-101.SCH 3015
5 XBRL LABEL FILE iccc-20240408_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE iccc-20240408_pre.xml EX-101.PRE 22359
18 EXTRACTED XBRL INSTANCE DOCUMENT ea0203573-8k_immucell_htm.xml XML 3482
Mailing Address 56 EVERGREEN DRIVE PORTLAND ME 04103
Business Address 56 EVERGREEN DR PORTLAND ME 04103 2078782770
IMMUCELL CORP /DE/ (Filer) CIK: 0000811641 (see all company filings)

IRS No.: 010382980 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12934 | Film No.: 24833577
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)